Business Wire

General Counsels Accelerate Technology Adoption to Tackle Compliance Pressures

Share

Technology and automation upgrades top GCs’ strategic agenda this year97% have already adopted generative AI tools72% anticipate rising legal and regulatory costs over the next three years

General counsels (GCs) across the globe are rapidly adopting technology, including generative artificial intelligence (AI), to optimize legal operations and stay on top of growing compliance pressures. This is according to new research conducted among 350 GCs and legal compliance officers across key global markets commissioned by CSC, the world’s leading provider of global business administration and compliance solutions.

CSC’s study1, General Counsel Barometer 2025, reveals that upgrading technology and automation sits firmly at the top of legal departments’ strategic priorities for the year ahead. The majority of legal departments (97%) are already using generative AI, with 49% saying the technology is significantly helping their legal teams.

The most widely reported benefits of AI tools include handling larger volumes of work more efficiently (66%), improving processing times (40%), and enhancing fraud detection and risk management (41%)—highlighting technology’s role in easing pressure on stretched legal teams and strengthening operational resilience.

“Even a year ago, everyone was interested in AI, but at the same time, were still standing on the sidelines and asking how trustworthy it was,” said Thijs van Ingen, global head of Corporate Solutions at CSC. “We’re now seeing real added value and productivity gains, particularly in complex areas like M&A. The shift towards tech-enabled partners shows GCs are acting decisively to modernize their departments in the face of mounting operational pressure.”

Yet confidence is tempered by caution. 72% of GCs have implemented internal governance policies to manage AI use, citing fraud, data privacy, and third-party risks as their top concerns.

“AI is here to stay—but responsible use is key,” added Ian McConnel, chief legal officer at CSC. “GCs are rightly focused on governance, accuracy, and data integrity. As legal teams evolve, they’re becoming leaders in embedding safe, effective AI into core business processes—but success will depend on ensuring the data sets behind these tools are both accurate and robust.”

These shifts are happening against a backdrop of rising compliance demands. Nearly three-quarters (72%) of GCs expect legal and regulatory costs to increase in the next three years, yet only 27% say they feel “very prepared” for new requirements such as expanded beneficial ownership disclosures. The changing regulatory landscape was cited as the number one risk to legal operations in 2025.

As well as embracing technology, nearly six-in-10 (58%) GCs report increased outsourcing to specialist partners—a move driven by resourcing constraints and the need for scalable, tech-enabled support across multiple jurisdictions.

“As organizations pursue global expansion, GCs are leading the charge,” adds van Ingen. “By embedding smarter systems and forming strategic partnerships, GCs are playing a pivotal role in helping their organizations manage risk, drive efficiency, and scale legal operations globally. This marks a defining shift in the role of legal function, where GCs are guiding their organizations into a more agile, tech-enabled future.”

To receive a copy of CSC’s General Counsel Barometer 2025 report, please contact Hassan Ali at cscteam@citigatedewerogerson.com.

1CSC, in partnership with Pure Profile, surveyed 350 general counsels and legal compliance officers in the Americas, Europe including UK, and Asia Pacific in 2025. Survey respondents were drawn from a range of industry sectors including communications, banking and financial services, healthcare, insurance, law, and real estate.

About CSC

CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250519574808/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye